Double-blind study of treatment with LCZ696 in asian elderly patients with essential hypertensio
- Conditions
- Essential Hypertension
- Registration Number
- JPRN-jRCT2080221938
- Lead Sponsor
- ovartis Pharma K.K.
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Sex
- All
- Target Recruitment
- 576
Patients must give written informed consent before any assessment is performed
- Patients with essential hypertension, untreated or currently taking antihypertensive therapy must have a mean sitting systolic blood pressure(msSBP) >= 150 mmHg and < 180 mmHg
- Patients must be able to communicate and comply with all study requirements and demonstrate good medication compliance
- Patients with severe hypertension. Patients with history of angioedema, drug-related or otherwise
- Patients with history or evidence of a secondary form of hypertension
- Transient ischemic cerebral attack (TIA) during the 12 months prior to Visit 1 or any history of stroke
- History of myocardial infarction, coronary bypass surgery or any percutaneous coronary intervention (PCI) during the 12 months prior to Visit 1
- Current angina pectoris requiring medication (other than patients on a stable dose of oral or topical nitrates)
- Patients with Type 1 or Type 2 diabetes mellitus who are not well controlled and are not on a stable dose of antidiabetic medication
- Patients with previous or current diagnosis of heart failure (NYHA Class II-IV)
- Patients with a clinically significant valvular heart disease at the time of screening
- Women of child-bearing potential, who do not use adequate birth control methods
Other protocol-defined inclusion/exclusion criteria may apply
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method